Mayor mortalidad cardiovascular en pacientes con hiperfosfatemia

1. Weisinger JR, Bellorin-Font E. Magnesium and phosphorus. Lancet. 1998;352:391-396.
2. Sitara D, Razzaque MS, Hesse M, et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004;23:421-432.
3. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45-51.
4. Morishita K, Shirai A, Kubota M, et al. The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr. 2001;131:3182-3188.
5. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-1483.
6. Ishimura E, Taniwaki H, Tabata T, et al. Cross-sectional association of serum phosphate with carotid intima-medial thickness in hemodialysis patients. Am J Kidney Dis. 2005;45:859-865.
7. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996;27:394-401.
8. Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation. 2002;106:100-105.
9. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorusand calcium _ phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607-617.
10. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO4, Ca_PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131-2138.
11. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520-528.
12. Tonelli M, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112:2627-2633.
13. Arking DE, Atzmon G, Arking A, et al. Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke,and longevity. Circ Res. 2005;96:412-418.
14. Arking DE, Becker DM, Yanek LR, et al. KLOTHO allele status and the risk of earlyonset occult coronary artery disease. Am J Hum Genet. 2003;72:1154-1161.
15. Low AF, O’Donnell CJ, Kathiresan S, et al. Aging syndrome genes and premature coronary artery disease. BMC Med Genet. 2005;6:38.
16. Kannel WB, Feinleib M, McNamara PM, et al. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979;110:281-290.
17. Kannel WB, Wolf PA, Garrison RJ, eds. Some risk factors related to the annual incidence of cardiovascular disease and death in pooled repeated biennial measurements: Framingham Heart Study, 30-year follow up. In: The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, Md: National Heart, Lung, and Blood Institute; 1987:34. NIH publication 87-2703.
18. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1-S266.
19. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
20. Coresh J, Astor BC, McQuillan G, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis. 2002;39:920-929.
21. Cox DR. Regression models and life tables J R Stat Soc [Ser B]. 1972;34:187-220.
22. Hosmer DW, Lemeshow S. Applied Survival Analysis. New York, NY: John Wiley & Sons; 1999.
23. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
24. Nam BH, Kannel WB, D’Agostino RB. Search for an optimal atherogenic lipid risk profile: from the Framingham Study. Am J Cardiol. 2006;97:372-375.
25. Froissart M, Rossert J, Jacquot C, et al. Predictive performance of the Modification of Diet in Renal Disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005;16:763-773.
26. Hastie T, Tibshirani R. Generalized additive models for medical research. Stat Methods Med Res. 1995;4:187-196.
27. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology. 1995;6:356-365.
28. Menon V, Greene T, Pereira AA, et al. Relationship of phosphorus and calciumphosphorus product with mortality in CKD. Am J Kidney Dis. 2005;46:455-463.
29. Kalaitzidis R, Tsimihodimos V, Bairaktari E, et al. Disturbances of phosphate metabolism: another feature of metabolic syndrome. Am J Kidney Dis. 2005;45:851-858.
30. Portale AA, Halloran BP, Murphy MM, et al. Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. J Clin Invest. 1986;77:7-12.
31. Portale AA, Halloran BP, Morris RC Jr. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest.1989;83:1494-1499.
32. Zittermann A, Schleithoff SS, Tenderich G, et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41:105-112.
33. Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997;96:1755-1760.
34. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:E10-E17.
35. Chen NX, O’Neill KD, Duan D, et al. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int. 2002;62:1724-1731.
36. Giachelli CM, Speer MY, Li X, et al. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res. 2005;96:717-722.
37. Giachelli CM. Ectopic calcification: gathering hard facts about soft tissue mineralization. Am J Pathol. 1999;154:671-675.
38. Silverberg SJ, Shane E, Clemens TL, et al. The effect of oral phosphate administration on major indices of skeletal metabolism in normal subjects. J Bone Miner Res. 1986;1:383-388.
39. Grey A, Mitnick MA, Masiukiewicz U, et al. A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology. 1999;140:4683-4690.
40. Mitnick MA, Grey A, Masiukiewicz U, et al. Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. Am J Physiol Endocrinol Metab. 2001;280:E405-E412.
41. Calvo MS, Park YK. Changing phosphorus content of the U.S. diet: potential for adverse effects on bone. J Nutr. 1996;126(suppl):1168S-1180S.
42. Portale AA, Halloran BP, Morris RC Jr. Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus: implications for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest. 1987;80:1147-1154.
43. Silverberg SJ, Shane E, de la Cruz L, Segre GV, Clemens TL, Bilezikian JP. Abnormalities in parathyroid hormone secretion and 1,25-dihydroxyvitamin D3 formation in women with osteoporosis. N Engl J Med. 1989;320:277-281.
44. Institute of Medicine. Dietary Reference Intakes for Calcium Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academy Press; 1999:147-380.
45. Sax L. The Institute of Medicine’s “Dietary Reference Intake” for phosphorus: a critical perspective. J Am Coll Nutr. 2001;20:271-278.
46. Wyshak G. Teenaged girls, carbonated beverage consumption, and bone fractures. Arch Pediatr Adolesc Med. 2000;154:610-613.